Amisulpride

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Amisulpride
   1. Pharmacist Assessment Report
   2. Amisulpride: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Amisulpride: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Amisulpride, so there is currently no new predicted indication. The drug’s recorded uses are listed below; none are recorded for this drug at present.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
8594H	Amisulpride Sandoz Pharma	Tablet 100 mg	Valid

Cytotoxicity

Not applicable. Amisulpride is not an antineoplastic drug, so this section is omitted.

Safety Considerations

Warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.

Drug interactions: A screen returned 100 interactions in total, and the first 20 are in the compiled data. The main ones listed are:

• Major: cisapride, clarithromycin, dolasetron, granisetron, levofloxacin and metoclopramide. Most of these are QT-prolonging or dopamine-related combinations, and the interaction details are not given in the data.
• Moderate: famotidine, epinephrine, hydrocortisone, amphotericin B (including the lipid complex), several laxatives (bisacodyl, castor oil, glycerin, lactitol, lactulose, magnesium citrate, magnesium hydroxide) and loperamide.
• Minor: metronidazole.

The literature also flags hyperprolactinaemia as a recognised adverse effect, and one trial (NCT04446234) is evaluating QTc prolongation. Neither point replaces the PI.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---